A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Investigating the Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery

The purpose of this study is to explore the safety and tolerability of BGE-117 and gain information on the effectiveness of different doses when given to patients 65 years or older with moderate to severe anemia following major hip surgery. BGE-117 is given once daily in a capsule by mouth for up to 12 weeks. Patients are also given oral iron supplements. Anemia following surgery has been associated with decreases in patient functioning. This study will measure improvement of anemia, as well as various patient functioning.

Start Date01 Apr 2022

Sponsor / Collaborator

BioAge Labs, Inc.Startup

NCT04815603 / WithdrawnPhase 2

A Phase 2a, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging

The primary objectives of this study to evaluate the safety, tolerability and efficacy of BGE-117 in the treatment of anemia of aging in participants ≥ 65 years of age.

Start Date22 Mar 2021

Sponsor / Collaborator

BioAge Labs, Inc.Startup

NCT03595202 / CompletedPhase 1

Phase I Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)

To investigate the safety, pharmacokinetics and pharmacodynamics of TS-143 when administered 3 times a day for 10 days to healthy Japanese adult males using placebo-controlled, double-blind, dose escalation study design.

Start Date03 Apr 2017

Sponsor / Collaborator

Taisho Pharmaceutical Co., Ltd.

100 Clinical Results associated with TS-143

100 Translational Medicine associated with TS-143

100 Patents (Medical) associated with TS-143

Literatures (Medical) associated with TS-143

01 Nov 2021·Biological and Pharmaceutical BulletinQ4 · MEDICINE

TP0463518 (TS-143) Ameliorates Peptidoglycan-Polysaccharide Induced Anemia of Inflammation in Rats

Q4 · MEDICINE

Article

Author: Uchida, Saeko ; Yamamoto, Koji ; Takahashi, Teisuke ; Kato, Sota

TP0463518 (TS-143) is a competitive prolyl hydroxylase 1/2/3 pan-inhibitor, and has been shown to specifically stabilize hypoxia-inducible factor-2 alpha in the liver to increase erythropoietin production. While TP0463518 has been shown to improve renal anemia, its effect on anemia of inflammation is still unknown. In this study, we created a rat model of anemia of inflammation by administering peptidoglycan-polysaccharide (PG-PS) to Lewis rats; the PG-PS-treated rats developed anemia within 2 weeks after the PG-PS challenge. The hematopoietic effects of oral TP0463518 administration at 10 mg/kg once daily for 6 weeks were examined in this rat model. The hematocrit values in the TP0463518-treated group increased significantly from 32.8 ± 0.8 to 44.5 ± 2.1% after the treatment, which was comparable to that in the healthy control group. The change of the mean corpuscular volume following TP0463518 treatment was similar to that in the healthy control group up to week 4, and significantly higher than that in the vehicle-treated group. TP0463518 increased divalent metal transporter 1 and duodenal cytochrome b expressions in the intestine. Conversely, TP0465318 did not exert any effects on the expressions of genes involved in iron metabolism in the liver, even though TP0463518 dramatically increased erythropoietin expression. Furthermore, TP0463518 had no effect on the expressions of inflammation markers in the liver. These results suggest that TP0463518 increased iron absorption and improved anemia of inflammation without exacerbating liver inflammation. TP0463518 appears to have an acceptable safety profile and could become a useful new therapeutic option for anemia of inflammation.

01 Feb 2021·Journal of Hazardous MaterialsQ1 · ENVIRONMENTAL SCIENCE & ECOLOGY

Dynamic interactions of Trichoderma harzianum TS 143 from an old mining site in Turkey for potent metal(oid)s phytoextraction and bioenergy crop farming

Q1 · ENVIRONMENTAL SCIENCE & ECOLOGY

Article

Author: Terzi, Ertugrul ; Eltem, Rengin ; Gedik, Kenan ; Pehlivan, Necla

Despite high pollution risk, the termination of mining practices is not in question in the current era in line with the growing needs of beings. Instead, the rehabilitation by phytoremediation restores the economic and aesthetic values of the damaged locale. Here, potentially toxic elements (PTEs) tolerant 29 Trichoderma isolates from mining sites located foothills of Turkey`s NE Black Sea coast were isolated. The highest tolerant strain (As 1400 mg L^-1, Cd 1200 mg L^-1, Cu 2000 mg L^-1, Pb 2100 mg L^-1, Zn 3000 mg L^-1) was characterized with translation elongation factor1 alpha (tef-1α) barcode and deposited in the GenBank. The PTEs removal strength of novel Trichoderma harzianum TS143 was highest for Pb (58%) and the lowest for As (8.5%) in the order of Pb > Cd > Cu > Zn > As. While bioleaching capacity was highest in Cd with 30%, the lowest was for As (8%). TS143 was found remarkably effective on all the physicochemical parameters in the shoot and root tissues of maize. The increase in the carbohydrate content (33.50%) proves the potential usage of the contaminated maize plants in bioenergy production. Core sustainable agents with their mesh type robust hyphal structure enfolding PTEs such as TS143 contribute to the phytoremediation technology along with potential plant biomass management for the biodiesel industry.

News (Medical) associated with TS-143

16 Jun 2022

·www.prnewswire.com

Worldwide Anti-aging Therapeutics Industry to 2040 - Rising Aging Population is Driving Growth

DUBLIN, June 16, 2022 /PRNewswire/ -- The "Anti-aging Therapeutics Market - Distribution by Type of Molecule, Type of Aging and Key Geographies - Industry Trends and Global Forecasts, 2022-2040" report has been added to ResearchAndMarkets.com's offering. This report features an extensive study of the current market landscape and future potential of anti-aging therapeutics over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. The advancements in health care and available technologies have inadvertently led to an increase in the life expectancy of individuals. However, this has also led to a rise in the aging population worldwide. According to the United Nations, the aforementioned trend is one of the key transformations observed in the 21st century; it is expected to have an impact on all sections of the society. Aging is linked to a variety of diseases, including cardiovascular disorders, neurodegenerative disorders, oncological disorders and musculoskeletal disorders, which further puts heavy economic and psychological burden on the patients, their families and the society. As per the World Health Organization, in 2020, close to 1 billion people were estimated to be aged 65 or above, globally. In addition, the share of elderly population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging biology is still a largely unexplored field, in terms of the development of safe and effective novel pharmacotherapies. Anti-aging therapeutics, therefore, is an emerging field of medical science focused on reducing or reversing the underlying causes of aging through different mechanisms, in order to extend healthy lifespan of humans. Given the rapidly growing aging population, the ongoing efforts to discover drugs that enhance the lifespan of an individual by targeting the pathogenesis of aging have become a popular topic for research. At present, various anti-aging products and devices, including direct-to-consumer nutraceuticals, plastic surgeries, cosmetics, skincare products and devices, are available in the market to slow the process of aging. Further, several start-ups and academic / research institutes across the world are evaluating various types of anti-aging therapeutics, including stem cell therapies, metformin, rapamycin, resveratrol and senolytics (drugs that selectively clear senescent cells), in multiple preclinical / clinical studies. Owing to the encouraging results demonstrating the ability of novel drugs in delaying the aging process, capital investments worth USD 4 billion have been made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid to long-term. Amongst other elements, the report includes: A detailed assessment of the current market landscape of anti-aging therapeutics, featuring information on phase of development (commercial, phase II, phase I / II, phase I, clinical (phase unknown), discovery / preclinical and undisclosed), type of aging (cellular aging, metabolic aging, immune aging, others and undisclosed), type of molecule (biologics and small molecules), mechanism of action (senolytic, cell regeneration, mammalian target of rapamycin (mTOR) inhibitor / modulator, adenosine monophosphate (AMP)-kinase / AMP activator, mitochondria inhibitor / modulator and others) and type of developer (industry and non-industry). In addition, the chapter features analyses of anti-aging therapeutic developers based on parameters, such as year of establishment, company size, location of headquarters and leading developers (in terms of number of pipeline candidates). A competitiveness analysis of anti-aging therapeutic developers, based on various relevant parameters, namely supplier power (based on the experience of the developer) and company competitiveness (based on highest phase of development, type of aging and type of molecule). An analysis of partnerships that have been inked by stakeholders engaged in this domain, during the period 2018-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, most active players (in terms of number of partnerships), type of partner and regional distribution of collaborations. A detailed analysis of investments that have been made into companies which are developing proprietary anti-aging therapeutics, during period 2018-2022. The various types of funding instances reported in this domain include pre-seed financing, seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants, crowdfunding, and donations. An in-depth analysis of the various patents that have been filed / granted related to anti-aging therapeutics, during 2018-2022, taking into consideration parameters, such as publication year, type of patent, geographical region, CPC symbols, key focus areas, type of applicant, patent age and leading players (in terms of size of intellectual property portfolio). It also features a patent benchmarking analysis and a detailed valuation analysis. A detailed review of more than 220 peer-reviewed, scientific articles related to research on anti-aging therapeutics, during the period 2018-2022, based on several relevant parameters, such as year of publication, type of publication, popular keywords and geography of affiliations. The chapter also provides information on the most popular publisher, most popular journal, most popular affiliations and most popular funding institutes (in terms of number of articles published). A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors. Elaborate profiles of prominent players engaged in the development of anti-aging therapeutics, featuring a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook. Key Questions Answered Who are the leading players engaged in the development of anti-aging therapeutics? What types of partnership models are commonly adopted by industry stakeholders engaged in this industry? Who are the key investors in the anti-aging therapeutics domain? How is the intellectual property landscape in this field likely to evolve in the foreseen future? What is the evolving trend of publications focused on anti-aging therapeutics? What are the key value drivers that are likely to influence the evolution of this upcoming market? How is the current and future market opportunity likely to be distributed across key market segments? Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. MARKET LANDSCAPE 5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Assumptions and Key Parameters 5.3. Methodology 5.4. Anti-aging Therapeutics: Company Competitiveness Analysis 5.4.1. Small Companies 5.4.2. Mid-sized and Large Companies 6. PARTNERSHIPS AND COLLABORATIONS 6.1. Chapter Overview 6.2. Anti-aging Therapeutics: Partnerships and Collaborations 6.2.1 Analysis by Year of Partnership 6.2.2. Analysis by Type of Partnership 6.2.3. Analysis by Year and Type of Partnership 6.2.4. Leading Players: Analysis by Number of Partnerships 6.2.5. Analysis by Type of Partner 6.2.6. Analysis by Type of Agreement 6.2.7. Analysis by Region 6.2.7.1. Intercontinental and Intracontinental Deals 6.2.7.2. International and Local Deals 7. FUNDING AND INVESTMENTS 7.1. Chapter Overview 7.2. Anti-aging Therapeutics: Funding and Investments 7.2.1. Analysis of Instances by Year 7.2.2. Analysis of Amount Invested by Year 7.2.3 Analysis of Instances by Type of Funding 7.2.4. Analysis of Amount Invested by Type of Funding 7.2.5. Analysis by Type of Investor 7.2.6. Analysis by Focus Area 7.2.7. Analysis of Amount Invested by Region 7.2.8. Analysis of Amount Invested by Country 7.2.9. Most Active Investors: Analysis by Number of Instances 7.2.10. Most Active Players: Analysis by Number of Instances 7.2.11. Most Active Players: Analysis by Amount Invested 8. PATENT ANALYSIS 8.1. Chapter Overview 8.2. Scope and Methodology 8.3. Anti-aging Therapeutics: Patent Analysis 8.3.1. Analysis by Type of Patent 8.3.2. Analysis by Patent Publication Year 8.3.3. Analysis of Granted Patents by Year 8.3.4. Analysis by Geography 8.3.5. Analysis by CPC Symbols 8.3.6. Analysis by Type of Applicant 8.3.7. Analysis by Emerging Focus Areas 8.3.8. Analysis by Patent Age 8.3.9. Leading Industry Players: Analysis by Number of Patents 8.3.10. Leading Non-Industry Players: Analysis by Number of Patents 8.3.11. Leading Individual Assignees: Analysis by Number of Patents 8.4. Anti-aging Therapeutics: Patent Benchmarking 8.4.1. Analysis by Patent Characteristics 8.5. Anti-aging Therapeutics: Patent Valuation 9. PUBLICATION ANALYSIS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. Anti-aging Therapeutics: Publication Analysis 10. PORTER'S FIVE FORCES ANALYSIS 11. COMPANY PROFILES 11.1. AgelessRx 11.1.1. Company Overview 11.1.2. Product Portfolio 11.1.3. Recent Developments and Future Outlook 11.2. ANOVA Institute for Regenerative Medicine 11.2.1. Company Overview 11.2.2. Product Portfolio 11.2.3. Recent Developments and Future Outlook 11.3. Betterhumans 11.3.1. Company Overview 11.3.2. Product Portfolio 11.3.3. Recent Developments and Future Outlook 11.4. BioAge Labs 11.4.1. Company Overview 11.4.2. Product Portfolio 11.4.3. Recent Developments and Future Outlook 11.5. bioXcellerator 11.5.1. Company Overview 11.5.2. Product Portfolio 11.5.3. Recent Developments and Future Outlook 11.6. Cambrian Biopharma 11.6.1. Company Overview 11.6.2. Product Portfolio 11.6.3. Recent Developments and Future Outlook 11.7. Gero.ai 11.7.1. Company Overview 11.7.2. Product Portfolio 11.7.3. Recent Developments and Future Outlook 11.8. Mayo Clinic 11.8.1. Company Overview 11.8.2. Product Portfolio 11.8.3. Recent Developments and Future Outlook 11.9. Rejuvenate Bio 11.9.1. Company Overview 11.9.2. Product Portfolio 11.9.3. Recent Developments and Future Outlook 11.10. UT Health San Antonio 11.10.1. Company Overview 11.10.2. Product Portfolio 11.10.3. Recent Developments and Future Outlook 12. MARKET FORECAST AND OPPORTUNITY ANALYSIS 12.1. Forecast Methodology and Key Assumptions 12.2. Global Anti-aging Therapeutics Market, 2022-2040 12.2.1. Anti-aging Therapeutics Market: Analysis by Type of Molecule 12.2.2. Anti-aging Therapeutics Market: Analysis by Type of Aging 12.2.3. Anti-aging Therapeutics Market: Analysis by Geography 12.2.3.1. Anti-aging Therapeutics Market in North America, 2022-2040 12.2.3.2. Anti-aging Therapeutics Market in Europe, 2022-2040 12.2.3.3. Anti-aging Therapeutics Market in Asia Pacific, 2022-2040 12.2.3.4. Anti-aging Therapeutics Market in Rest of the World, 2022-2040 12.2.4. Anti-aging Therapeutics: Forecast of Individual Product Sales 12.2.4.1. bioXgel (PRP) (bioXcellerator): Estimated Sales Revenues 12.2.4.2. AR-100 (Rejenevie Therapeutics): Estimated Sales Revenues 12.2.4.3. BGE-117 (BioAge Labs): Estimated Sales Revenues 12.2.4.4. Dasatinib and Quercetin (TruDiagnostic): Estimated Sales Revenues 12.2.4.5. MYMD-1 (MyMD Pharmaceuticals): Estimated Sales Revenues 12.2.4.6. TRIIM Treatment (Intervene Immune): Estimated Sales Revenues 12.2.4.7. Rapamycin (AgelessRx): Estimated Sales Revenues 12.2.4.8. Sarconeos (BIO101) (Biophytis): Estimated Sales Revenues 13. EXECUTIVE INSIGHTS 13.1. Chapter Overview 13.2. Gero.ai 13.2.1 Company Snapshot 13.2.2. Interview Transcript: Peter Fedichev (Co-founder and Chief Executive Officer) 13.3. Betterhumans 13.3.1. Company Snapshot 13.3.2. Interview Transcript: James Clement (President) 13.4. CytoMed Therapeutics 13.4.1. Company Snapshot 13.4.2. Interview Transcript: Wee Kiat Tan (Chief Operating Officer) 13.5. Cambrian Biopharma 13.5.1 Company Snapshot 13.5.2. Interview Transcript: Rosa Argyropoulos (Senior Director of Global Corporate Communications) 13.6. Landmark Medical Centre 13.6.1 Company Snapshot 13.6.2. Interview Transcript: Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist) 14. APPENDIX I: TABULATED DATA 15. APPENDIX I1: LIST OF COMAPANIES AND ORGANIZATIONS For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

Cell TherapySmall molecular drugCollaborate

31 May 2022

·www.biospace.com

BioAge CEO to Lead a Panel Discussion at the BIO 2022 Conference: “Targeting Aging Pathways to Treat Chronic Disease” — June 14, 2022, 11 AM

Company CEO and CBO will be available throughout BIO 2022 for partnering meetings RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that Kristen Fortney, PhD, CEO and Co-Founder of BioAge, will lead a panel discussion at the BIO International Conference held June 13–16, 2022 in San Diego, California (“BIO 2022”). Event details are as follows: Title: Targeting Aging Pathways to Treat Chronic Disease Date/Time Tuesday, June 14, 2022, 11:00 AM – 12:00 PM PDT Location Upper Level, Session Room 1B, San Diego Convention Center Moderator Kristen Fortney, PhD, CEO of BioAge Labs Panelists Ann Beliën, PhD, CEO of Rejuvenate Bio Steven Braithwaite, PhD, CEO and CSO of Alkahest Matt Buckley, PhD, Co-founder of Retro Biosciences Alex Zhavoronkov, PhD, CEO of Insilico Medicine Registration: Link “Aging is the primary driver of many serious diseases. Together with other leading companies in this new and exciting space, we will discuss the challenge and promise of developing drugs that address this enormous unmet clinical need,” said Dr. Fortney. “Our BIO 2022 panel will be a fantastic event of deep interest to pharma, investors, founders, and researchers in the emerging field of longevity-based therapeutics.” Opportunities for partnership with BioAge Dr. Fortney and Peng Leong, PhD, MBA, BioAge’s chief business officer (CBO) and Head of Brain Aging, will be available throughout the conference to meet to discuss partnerships and opportunities with interested parties. Attendees can send meeting requests to BioAge via the BIO 2022 partnering system [link] or via the contact information in this release. “BioAge’s discovery platform, based on analysis of human longevity data, has already yielded multiple clinical assets including our apelin receptor agonist for treatment of muscle aging, as well as novel advanced lead compounds such as our recently announced novel family of NLRP3 inhibitors,” said Dr. Leong. “The platform will continue to reveal promising new targets and therapies to treat diseases of aging, and we look forward to meeting potential partners, collaborators, and investors face to face at this extraordinary conference.” BIO 2022 is organized by the Biotechnology Innovation Organization (BIO), the world’s largest advocacy association for the biotech industry. The mission of BIO 2022 is to promote global partnerships, collaboration, and thought leadership in biotechnology. Registration for the conference is open. [link] About BioAge Labs, Inc. BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records to map the key molecular pathways that impact healthy human aging. By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat or prevent age-related disease in entirely new ways. BioAge has multiple clinical programs in its growing portfolio targeting muscle, immune, and brain aging, including BGE-105 (Phase 1: muscle atrophy), BGE-175 (Phase 2: COVID-19, influenza, and beyond), and BGE-117 (Phase 2: muscle aging), as well as proprietary NLRP3 inhibitors (preclinical development, inflammatory and age-related neurological diseases). To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others. View source version on businesswire.com: Contacts PR: Chris Patil, media@bioagelabs.com IR: Daniel Ferry, daniel@lifesciadvisors.com Partnering: partnering@bioagelabs.com Web: Source: BioAge Labs, Inc. View this news release online at:

Collaborate

15 Apr 2021

·www.biospace.com

BioAge Makes A Big Bet on Amgen Drug To Target Muscle Aging

BioAge Co-founder and CEO, Kristen Fortney/Photo Courtesy of BioAge Labs. BioAge Labs is not content to stand idly by and accept the status quo of aging-related muscle deterioration. The California-based biotech, which closed a $90 million Series C in December to advance its pipeline of drugs that target the molecular causes of aging, on Wednesday announced an exclusive agreement with Amgen to develop and commercialize an APJ agonist aimed at ameliorating muscle aging. BGE-105 (formerly AMG 986) mimics the production of apelin, a peptide that has been found in animal studies to improve muscle regeneration and decrease mouse frailty. “We found in our datasets that people who have higher levels of apelin peptide were living longer and were less frail when they were older, and also had improved cognitive function,” said BioAge co-founder and CEO, Kristen Fortney, Ph.D. The company’s genomics-driven discovery platform is based on human blood samples from healthy middle-aged people going back 50 years. These human aging cohorts, along with BioAge’s overall strategy, help to de-risk drug development in a space inherently at odds with the traditional regulatory landscape. “This is the low-hanging fruit in the aging space, copying what’s already working in humans by studying humans who are already living really long and living really healthy,” Fortney said. “People always think, how do you even do clinical development? We’re really committing to mechanisms that we think have long-term potential to really improve the healthspan…but along the way, there has to be a very practical model indication where we can get an efficient clinical readout. So there’s a clear-cut regulatory payer commercial strategy.” Following customary protocol, proving that a drug prevents aging or age-related diseases would, of course, quite literally take a lifetime. BioAge selects pathways that appear to be close to clinical translation and which already have assets that have been through Phase I and known to hit their target. “Then we can just bring them in and go directly to a severe disease in older people,” Fortney said. BGE-105 is the third in a series of “big bets” that BioAge has made during the past 12 months. The first one is BGE-117, licensed from Taisho Pharmaceutical Co, , an HIF-PH inhibitor being tested for unexplained anemia of aging, which will be developed for indications related to muscle weakness. The second is BGE-175, licensed from Shionogi Pharma Inc., a PGD2 DP1 receptor inhibitor being tested in COVID-19 patients. It will ultimately be developed to treat disorders of the aging immune system. “Your immune system becomes so much more vulnerable as you get older and that’s important every year with the flu. People over the age of 85 are 30-fold more likely to be hospitalized. It’s funny because I used to have to explain the concept of immune aging, but now everybody gets it, because it’s so clear that nearly all the morbidity and mortality in COVID-19 is driven by immune aging,” Fortney said. BioAge, which very recently initiated phase II trials for their first two clinical programs, BGE-175 and BGE-117, plans to launch a phase I trial for BGE-105 to prove target engagement in the first quarter of 2022. The drug had a tolerable safety profile in a 2019 phase I trial consisting of 198 people. Under the terms of the agreement, BioAge will give Amgen an upfront payment as well as development and regulatory milestone and royalties based on annual net sales. Amgen will also receive BioAge shares. When it comes to the aging space, Fortney said that the focus needs to be on the quality of the life being extended: “In the US, the average lifespan is in the low 80s, but the average health span is only in the low 60s, and that’s when you get your first age-related chronic disease that you then have for the rest of your life. So, there’s a big 20-year gap there where you’re just piling on diseases. It’s a poor quality of life and it’s also expensive for the healthcare system.”

Collaborate

100 Deals associated with TS-143

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute posthaemorrhagic anaemia	Phase 2	AU	BioAge Labs, Inc.Startup	01 Apr 2022
Anemia	Phase 2	US	BioAge Labs, Inc.Startup	30 Jan 2022
disorder of aging	Phase 2	AU	BioAge Labs, Inc.Startup	22 Mar 2021
Chronic Kidney Diseases	Preclinical	JP	Taisho Pharmaceutical Co., Ltd.	06 Oct 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

TS-143

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation